The emerging epidemic of heart failure with preserved ejection fraction

被引：6
作者：
Oktay A.A. [1 ]
Rich J.D. [1 ]
Shah S.J. [1 ]
机构：
[1] Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611
来源：
Current Heart Failure Reports | 2013年 / 10卷 / 4期
基金：
美国国家卫生研究院;
关键词：
Diastolic heart failure; Epidemiology; Pathophysiology; Prognosis; Risk estimation;
D O I：
10.1007/s11897-013-0155-7
中图分类号：
学科分类号：
摘要：
Heart failure with preserved ejection fraction (HFpEF), which currently represents approximately 50 % of heart failure (HF) cases, is common and associated with high morbidity and mortality. Understanding the epidemiology of HFpEF has been difficult due to the challenges in HFpEF diagnosis and the heterogeneous etiologies and pathophysiologies that underlie HFpEF. Nevertheless, several high-quality epidemiology and observational registry studies of HFpEF demonstrate that an increasing prevalence of HFpEF in both the outpatient and inpatient settings, coupled with a lack of evidence-based effective treatments for HFpEF, is resulting in an emerging epidemic of HFpEF. In this review, we discuss the emerging HFpEF epidemic, focusing on: (1) reasons for the rising prevalence of HFpEF; (2) the abnormalities in cardiac structure and function that dictate the transition from risk factors to HFpEF; (3) novel HFpEF mechanisms that may underlie the increase in HFpEF prevalence; (4) prognosis of HFpEF; and (5) risk prediction in HFpEF. We conclude with 10 unanswered questions on HFpEF epidemiology that will be important areas for future investigation. © 2013 Springer Science+Business Media New York.
引用
收藏
页码：401 / 410
页数：9
相关论文
共 84 条
[1]  
Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction, N Engl J Med, 355, 3, pp. 251-259, (2006)
[2]  
Bhatia R.S., Tu J.V., Lee D.S., Austin P.C., Fang J., Haouzi A., Et al., Outcome of heart failure with preserved ejection fraction in a population-based study, N Engl J Med, 355, 3, pp. 260-269, (2006)
[3]  
Fonarow G.C., Stough W.G., Abraham W.T., Albert N.M., Gheorghiade M., Greenberg B.H., Et al., Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF Registry, J Am Coll Cardiol, 50, 8, pp. 768-777, (2007)
[4]  
Shah S.J., Heitner J.F., Sweitzer N.K., Anand I.S., Kim H.Y., Harty B., Et al., Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial, Circ Heart Fail, 6, 2, pp. 184-192, (2012)
[5]  
Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., Et al., Heart disease and stroke statistics-2013 update: A report from the American Heart Association, Circulation, 127, 1, (2013)
[6]  
Jessup M., Brozena S., Heart failure, N Engl J Med, 348, 20, pp. 2007-2018, (2003)
[7]  
Paulus W.J., Tschope C., Sanderson J.E., Rusconi C., Flachskampf F.A., Rademakers F.E., Et al., How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology, Eur Heart J, 28, 20, pp. 2539-2550, (2007)
[8]  
Owan T.E., Redfield M.M., Epidemiology of diastolic heart failure, Prog Cardiovasc Dis, 47, 5, pp. 320-332, (2005)
[9]  
Caruana L., Petrie M.C., Davie A.P., McMurray J.J., Do patients with suspected heart failure and preserved left ventricular systolic function suffer from diastolic heart failure or from misdiagnosis? A prospective descriptive study, BMJ, 321, 7255, pp. 215-218, (2000)
[10]  
Lam C.S., Donal E., Kraigher-Krainer E., Vasan R.S., Epidemiology and clinical course of heart failure with preserved ejection fraction, Eur J Heart Fail, 13, 1, pp. 18-28, (2011)
123456789